Figure 5.

Total IgG and neutralizing antibodies anti-SARS-CoV-2 in the study participants. (A) Total IgG serum antibodies against the N protein of the SARS-CoV-2 in participants who developed mild or severe COVID-19 during the follow-up. (B) Percentage of neutralizing antibodies anti-SARS-CoV-2 in participants who developed mild or severe COVID-19 during the follow-up. We measured total IgG or neutralizing antibodies one month after clinical recovery of participants. Black bars represent the mild COVID-19 group. Gray bars represent the severe COVID-19 group. We expressed data as mean ± standard deviation. We compared data using the unpaired Student’s T-test and considered differences significant when P < 0.05. IgG, immunoglobulin G; SARS-CoV-2, severe acute respiratory syndrome coronavirus type 2; COVID-19, coronavirus disease 2019.